Cachexia is a risk factor for negative clinical and functional outcomes in patients receiving chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.
immunotherapy
metabolism
non-Hodgkin lymphoma
quality of life
risk factors
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
revised:
21
12
2021
received:
06
10
2021
accepted:
10
01
2022
pubmed:
11
2
2022
medline:
21
4
2022
entrez:
10
2
2022
Statut:
ppublish
Résumé
Cachexia is a muscle-wasting syndrome that is known to impact the clinical course of several cancer populations but has not been specifically investigated in patients receiving chimeric antigen receptor T (CAR-T) cell therapy. In this study, we investigated the relationship between cachexia markers and several cancer and functional outcomes in a pilot population of aggressive B-cell non-Hodgkin lymphoma patients receiving CAR-T. We found that the prognostic nutritional index was linked to progression-free survival, overall survival, and disability-free survival, while several additional weight and serum-based markers of cachexia were also associated with negative outcomes. These data prompt further investigation of cachexia markers in populations receiving CAR-T cell therapy.
Substances chimiques
Receptors, Antigen, T-Cell
0
Receptors, Chimeric Antigen
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
71-75Informations de copyright
© 2022 British Society for Haematology and John Wiley & Sons Ltd.
Références
Abramson JS. Anti-CD19 CAR T-cell therapy for B-cell non-Hodgkin lymphoma. Transfus Med Rev. 2020;34(1):29-33.
Byrne M, Oluwole OO, Savani B, Majhail NS, Hill BT, Locke FL. Understanding and managing large B cell lymphoma relapses after chimeric antigen receptor T cell therapy. Biol Blood Marrow Transplant. 2019;25(11):e344-51.
Baracos VE, Martin L, Korc M, Guttridge DC, Fearon KCH. Cancer-associated cachexia. Nat Rev Dis Prim 2018;4:17105. Available from: http://www.nature.com/articles/nrdp2017105
Mallard J, Gagez A-L, Baudinet C, Herbinet A, Maury J, Bernard PL, et al. C-reactive protein level: a key predictive marker of cachexia in lymphoma and myeloma patients. J Hematol. 2019;8(2):55-9.
Karmali R, Alrifai T, Fughhi IAM, Ng R, Chukkapalli V, Shah P, et al. Impact of cachexia on outcomes in aggressive lymphomas. Ann Hematol. 2017;96(6):951-6. Available from:. https://link.springer.com/article/10.1007/s00277-017-2958-1
Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016;127(26):3321-30. Available from:. http://ashpublications.org/blood/article-pdf/127/26/3321/1394163/3321.pdf
Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489-95. Available from:. http://www.ncbi.nlm.nih.gov/pubmed/21296615
Barker T, Fulde G, Moulton B, Nadauld LD, Rhodes T An elevated neutrophil-to-lymphocyte ratio associates with weight loss and cachexia in cancer. Sci Rep. 2020;10(1):7535.
Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, Bozzetti F, et al. ESPEN guidelines on nutrition in cancer patients. Clin Nutr. 2017;36(1):11-48.
Demirelli B, Babacan NA, Ercelep Ö, Öztürk MA, Kaya S, Tanrıkulu E, Khalil S, Hasanov R, Alan Ö, Telli TA, Koca S, Arıbal ME, Kuzan B, Dane F, Yumuk PF Modified glasgow prognostic score, prognostic nutritional index and ECOG performance score predicts survival better than sarcopenia, cachexia and some inflammatory indices in metastatic gastric cancer. Nutr Cancer 2021;73(2):230-8. Available from: https://www.tandfonline.com/doi/full/10.1080/01635581.2020.1749290
Shen Z, Wang F, He C, Li D, Nie S, Bian Z, et al. The value of prognostic nutritional index (PNI) on newly diagnosed diffuse large B-cell lymphoma patients: a multicenter retrospective study of HHLWG based on propensity score matched analysis. J Inflamm Res. 2021;14:5513-22. Available from:. https://www.dovepress.com/the-value-of-prognostic-nutritional-index-pni-on-newly-diagnosed-diffu-peer-reviewed-fulltext-article-JIR
Burkart M, Schieber M, Basu S, Shah P, Venugopal P, Borgia JA, et al. Evaluation of the impact of cachexia on clinical outcomes in aggressive lymphoma. Br J Haematol. 2019;186(1):45-53. Available from:. https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.15889
Miyawaki T, Naito T, Kodama A, Nishioka N, Miyawaki E, Mamesaya N, et al. Desensitizing effect of cancer cachexia on immune checkpoint inhibitors in patients with advanced NSCLC. JTO Clin Res Reports. 2020;1(2):100020.
Ngo-Huang A, Parker NH, Bruera E, Lee RE, Simpson R, O’Connor DP, et al. Home-based exercise prehabilitation during preoperative treatment for pancreatic cancer is associated with improvement in physical function and quality of life. Integr Cancer Ther. 2019;18:1-10.
Naito T Evaluation of the true endpoint of clinical trials for cancer cachexia. Asia Pac J Oncol Nurs. 2019;6(3):227-33.